Abstract:Introduction: The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent anti-hyperglycemic activity, SGLT2 inhibitors are emerging as drugs with multifaceted therapeutic potential, evidenced for cardioprotective, renoprotective, antihypertensive, and neuroprotective activities. Continuous attempts are being accomplished through structural modification, development of new formulation, or combination with other drugs, to enhance the bioactivity spectrum of SGLT2 inhibitors for better management of diabetes and related complications. Areas covered: This review comprises a summary of patent applications, acquired using the Espacenet Patent Search database, concerning SGLT2 inhibitors from 2019 to 2023, with focus on improving therapeutic potentials in management of diabetes and metabolic complications. Expert opinion: SGLT2 inhibitors have provided an exciting treatment option for diabetes. Originally developed as anti-hyperglycemic agents, SGLT2 inhibitors exert pleiotropic metabolic responses and have emerged as promising antidiabetic agents with cardio-protective and reno-protective activities. Given their distinct therapeutic profile, SGLT2 inhibitors have revolutionized the management of diabetes and associated complications. Emerging evidences on their therapeutic potential against cancer, male reproductive dysfunctions, and neurodegenerative diseases indicate that further research in this field may unfold novel prospective on their plausible use in the management of other chronic conditions.

An updated patent review of glutaminase inhibitors (2019-2022).

Overview of the development of Glutaminase Inhibitors: Achievements and Future Directions.

SGLT2 inhibitors for the treatment of diabetes: a patent review (2019-23)

Gelatinase Inhibitors: a Patent Review (2011-2017)

Gamma Secretase Inhibitors: a Patent Review (2013 - 2015)

Design, Synthesis, and Pharmacological Evaluation of 2-(1-(1,3,4-thiadiazol-2-yl)piperidin-4-yl)ethan-1-ol Analogs As Novel Glutaminase 1 Inhibitors.

Glycine transporter-1 inhibitors: a patent review (2011–2016)

An updated patent review of Akt inhibitors (2016-present)

A Patent Review of Arginine Methyltransferase Inhibitors (2010–2018)

GLP-1R agonists for the treatment of obesity: a patent review (2015-present)

Design, Synthesis, and Biological Evaluation of Novel Glutaminase 1 Allosteric Inhibitors with an Alkane Chain Tail Group.

Discovery of Novel Glutaminase 1 Allosteric Inhibitor with 4-Piperidinamine Linker and Aromatic Heterocycles.

An updated patent review of AKT inhibitors (2020 - present)

Progress on Glucosidase Inhibitors

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present)

An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022)

Inhibitors of the GTPase KRASG12C in Cancer: a Patent Review (2019-2021).

Epidermal growth factor receptor inhibitors: a patent review (2010 - present).

A FGFR1 inhibitor patent review: progress since 2010

Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016–2019): a patent review

An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)